470 related articles for article (PubMed ID: 30691652)
1. CRISPR-Cas10 assisted editing of virulent staphylococcal phages.
Nayeemul Bari SM; Hatoum-Aslan A
Methods Enzymol; 2019; 616():385-409. PubMed ID: 30691652
[TBL] [Abstract][Full Text] [Related]
2. Strategies for Editing Virulent Staphylococcal Phages Using CRISPR-Cas10.
Bari SMN; Walker FC; Cater K; Aslan B; Hatoum-Aslan A
ACS Synth Biol; 2017 Dec; 6(12):2316-2325. PubMed ID: 28885820
[TBL] [Abstract][Full Text] [Related]
3. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CRISPR-Cas system in clinical Staphylococcus epidermidis strains revealed its potential association with bacterial infection sites.
Li Q; Xie X; Yin K; Tang Y; Zhou X; Chen Y; Xia J; Hu Y; Ingmer H; Li Y; Jiao X
Microbiol Res; 2016 Dec; 193():103-110. PubMed ID: 27825477
[TBL] [Abstract][Full Text] [Related]
5. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
Shen J; Zhou J; Chen GQ; Xiu ZL
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
[No Abstract] [Full Text] [Related]
6. CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages.
Martel B; Moineau S
Nucleic Acids Res; 2014 Aug; 42(14):9504-13. PubMed ID: 25063295
[TBL] [Abstract][Full Text] [Related]
7. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
Hwang S; Maxwell KL
CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
[TBL] [Abstract][Full Text] [Related]
8. Genetic Engineering of Therapeutic Phages Using Type III CRISPR-Cas Systems.
Hill CM; Hatoum-Aslan A
Methods Mol Biol; 2024; 2734():279-299. PubMed ID: 38066376
[TBL] [Abstract][Full Text] [Related]
9. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.
Goldberg GW; Jiang W; Bikard D; Marraffini LA
Nature; 2014 Oct; 514(7524):633-7. PubMed ID: 25174707
[TBL] [Abstract][Full Text] [Related]
10. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus.
Park JY; Moon BY; Park JW; Thornton JA; Park YH; Seo KS
Sci Rep; 2017 Mar; 7():44929. PubMed ID: 28322317
[TBL] [Abstract][Full Text] [Related]
11. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9.
Hynes AP; Rousseau GM; Lemay ML; Horvath P; Romero DA; Fremaux C; Moineau S
Nat Microbiol; 2017 Oct; 2(10):1374-1380. PubMed ID: 28785032
[TBL] [Abstract][Full Text] [Related]
12. Keeping crispr in check: diverse mechanisms of phage-encoded anti-crisprs.
Trasanidou D; Gerós AS; Mohanraju P; Nieuwenweg AC; Nobrega FL; Staals RHJ
FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077304
[TBL] [Abstract][Full Text] [Related]
13. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
Liu Q; Zhang H; Huang X
FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
[TBL] [Abstract][Full Text] [Related]
14. Current and future prospects for CRISPR-based tools in bacteria.
Luo ML; Leenay RT; Beisel CL
Biotechnol Bioeng; 2016 May; 113(5):930-43. PubMed ID: 26460902
[TBL] [Abstract][Full Text] [Related]
15. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
Modell JW; Jiang W; Marraffini LA
Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
[TBL] [Abstract][Full Text] [Related]
17. Genome Engineering of Virulent Lactococcal Phages Using CRISPR-Cas9.
Lemay ML; Tremblay DM; Moineau S
ACS Synth Biol; 2017 Jul; 6(7):1351-1358. PubMed ID: 28324650
[TBL] [Abstract][Full Text] [Related]
18. The Anti-CRISPR Story: A Battle for Survival.
Maxwell KL
Mol Cell; 2017 Oct; 68(1):8-14. PubMed ID: 28985512
[TBL] [Abstract][Full Text] [Related]
19. Degradation of Phage Transcripts by CRISPR-Associated RNases Enables Type III CRISPR-Cas Immunity.
Jiang W; Samai P; Marraffini LA
Cell; 2016 Feb; 164(4):710-21. PubMed ID: 26853474
[TBL] [Abstract][Full Text] [Related]
20. Phage Genetic Engineering Using CRISPR⁻Cas Systems.
Hatoum-Aslan A
Viruses; 2018 Jun; 10(6):. PubMed ID: 29921752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
